OCUGEN OCGN 深 沪
已收盘 12-12 16:00:00 美东时间
1.36
+0.060
+4.62%
华盛通- 最 高1.39
- 今 开1.31
- 成交量 404.82万股
- 最 低 1.30
- 昨 收 1.30
- 总市值 4.24亿
- 52周最高 1.90
- 市盈率 静 --
- 换手率 1.30%
- 52周最低 0.515
- 委 比 -52.19%
- 总股本 3.12亿
- 历史最高 18.77
- 量 比 1.36
- 振 幅 6.92%
- 历史最低 0.17
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Ocugen, Inc. announced that Dr. Shankar Musunuri, its Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025. Dr. Musunuri will discuss Ocugen’s novel modifier gene therapy platform, which aims to treat entire diseases, potentially benefiting large patient populations in rare and age-related blindness diseases. The fireside chat is titled "Fireside Chat with Aldeyra and Ocugen: Setting Si...
12-10 14:20
SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
11-27 04:13
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
<p>Ocugen, Inc. announced that Dr. Shankar Musunuri, its Chairman, CEO, and Co-founder, will present at NobleCon21 on December 3, 2025, in Boca Raton, FL. Dr. Musunuri will discuss Ocugen's progress toward achieving three Biologics License Applications (BLAs) in three years and provide updates on upcoming 2026 developments. The presentation will highlight Ocugen's modifier gene therapy platform, which addresses complex blindness diseases through ...
11-20 12:02
Ocugen Q3 Sales $1.752M Beat $550.000K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly sales of $1.752 million which beat the analyst consensus estimate of $550.000 thousand by 218.55 percent. This is a 54.23 percent increase over sales of $1.136 million the same
11-05 19:33
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
Ocugen reported third quarter 2025 financial results and business updates. Key highlights include progress on the Phase 2/3 GARDian3 trial for OCU410ST with 50% enrollment completed, execution of a licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea, and a $20 million registered direct offering. The company expects BLA filings in 2026 and 2027 for OCU400 and OCU410ST, respectively. Financially, Ocugen ended the quarter wit...
11-05 11:30
Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of Applied Digital Corp (NASDAQ:APLD) rose sharply in pre-market trading...
10-10 17:06
期权扫描 | POET期权成交放量44倍，一看涨期权暴涨超700%
SPX的看跌期权成交量256.91万张，看涨期权成交量209.99万张，看跌/看涨交易量比率约1.22，表明投资者押注该指数看跌意愿较强。
10-08 18:13
Ocugen to Present at Industry and Investor Conferences in October 2025
Ocugen, Inc., a biotechnology leader in gene therapies for blindness diseases, announced that its executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan’s 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit. Dr. Shankar Musunuri highlighted Ocugen’s goal of submitting three BLAs within three years and emphasized their commitment to advancing gene therapies. Abhi Gupta and Dr. Musunuri will del...
10-02 11:30
美股牛股 | 中概股恒峰科技上市累涨300%！加密货币公司Bakkt再度大涨17%
中概股恒峰科技大涨35%！上市累涨逾300%；加密货币公司Bakkt再度大涨17%，公司任命新董事会成员>>
09-24 17:18
